Lorvotuzumab
Based on 1 Customer Validation
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine.
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 339306-30-8
- Molecular Weight:146.44 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
NCAM1/CD56
Lorvotuzumab mertansine (IMGN901) is an ADC that links a potent anti-mitotic (DM1) via a disulfide linker to CD56 targeting antibodies (Lorvotuzumab). Lorvotuzumab mertansine against Wilms tumor, rhabdomyosarcoma, and neuroblastoma[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized NCAM-1/CD56 Protein, Human (HEK293, His, solution, HY-P75933) can bind Lorvotuzumab. The EC50 for this effect is 56.21 ng/mL. -
Loaded Lorvotuzumab on AHC2 biosensor, can bind NCAM-1/CD56 Protein, Human (HEK293, His-Avi, HY-P75932) with an affinity constant of 3.918E-09 M as determined in BLI assay. -
Flow Cytometry analysis of SK-N-SH cells with NCAM1/CD56 (red) with Lorvotuzumab (anti-NCAM1/CD56) (HY-P99372). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 339306-30-8
-
Appearance Liquid
-
Molecular Weight 146.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Lorvotuzumab]
-
Synonyms
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)